Holen Sie sich die Stockscreener-App
29.50
0.10%
-0.03
Handel nachbörslich:
29.00
-0.50
-1.69%
Metsera Inc Aktie (MTSR) Neueste Nachrichten
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut - Reuters
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 By Investing.com - Investing.com Australia
Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut - Smartkarma
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 - Investing.com
Metsera sees stock rally 54% following $275M IPO - MSN
Weight-loss drug developer Metsera raises $275 million in US IPO - MSN
Metsera sees stock rally 54% following $275M IPO (MTSR:NASDAQ) - Seeking Alpha
Metsera IPO opens 42% higher By Investing.com - Investing.com Nigeria
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut -January 31, 2025 at 01:02 pm EST - Marketscreener.com
Metsera Shares Rise Sharply in Nasdaq Debut -January 31, 2025 at 01:03 pm EST - Marketscreener.com
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon - MarketWatch
MTSR IPO NewsObesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - Renaissance Capital
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera Prices of Initial Public Offering - citybiz
Metsera, Maze raise a combined $415M in IPO double-header - FirstWord Pharma
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
MTSRMetsera, Inc. Latest Stock News & Market Updates - StockTitan
Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut - Smartkarma
Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha
GLP-1RA developer Metsera targets $289m IPO - Pharmaceutical Technology
Three biotechs go public as IPO momentum increases - The Pharma Letter
Obesity drug developer Metsera sets terms for $275M IPO - MSN
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation - Smartkarma
Metsera Seeks $289M Raise, $1.78B Valuation in IPO - BioSpace
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Metsera eyes $289M IPO to fund phase 3 weight loss trial - Fierce Biotech
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - Yahoo Finance
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO - MSN
Metsera outlines $250M IPO plans as obesity biotech competition rises - Endpoints News
Weight-loss drug developer Metsera reveals wider loss in US IPO filing - MSN
Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech - Smartkarma
2024’s Top 7 VC Raises in Biotech - BioSpace
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):